Immune regulation by microRNA implications for diagnosis and treatment of chronic disease development in aging people with rheumatoid arthritis (RA) and osteoarthritis (OA) as disease models.
Completed
- Conditions
- immune mediated chronic diseases10003816
- Registration Number
- NL-OMON33895
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
RA patients with comorbidity
1.Fulfilling the ACR classification criteria for RA
2.Age > 65 years
3.No treatment with DMARD (Disease Modifying Antirheumatic Drugs)
4.Presence of co-morbidity;Healthy Controls
1.Have no chronic disease
2.Age > 65 years;RA patients without comorbidity
1.Fulfilling the ACR classification criteria for RA
2.Age > 65 years
3.No treatment with DMARD (Disease Modifying Antirheumatic Drugs)
4.No co-morbidity at start of the study;For OA patients
1.Fulfilling the ACR classification criteria for OA
2.Age >65 years
3.No co-morbidity at start of the study
Exclusion Criteria
For all groups (RA, OA and HC)
1.No informed consent
2.Severe anaemia defined as a Hb of less than 6.0 gr/l
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>First, is there a relation between multi-morbidity and a certain IRP/ microRNA<br /><br>profile and the GFI.</p><br>
- Secondary Outcome Measures
Name Time Method <p>What changes in miRNA/ IRP are instrumental for the development of<br /><br>multi-morbidity? Such mechanistic insight could be useful to help or better<br /><br>define the IRP and could be a potential lead for therapeutic intervention.</p><br>